Search

Hydrogen is a potential energy carrier in comparison to conventional fuels due to its high energy content. Methane is an attractive source for 'on‐site' production of hydrogen by using membrane reformer due to its low cost. However, such reformers are not well studied and high temperature operation of steam methane reforming (SMR) makes the integration with membrane separation difficult. Further, the main product of SMR is CO and H2 in which CO has an inhibition effect on the membrane separation process. Therefore, it is vital to synthesize a low temperature and low CO selective catalyst for a suitable integration with membrane reformer. Nickel‐based catalyst is widely used for SMR due to its low cost and high catalytic activity. CeO2 is a favoured support as it mobilizes the lattice oxygen and reduces the coke formation and CO selectivity. Though several studies are reported on CeO2 based support, the effect of CeO2 surface morphology is not studied for SMR. In the current work, Ni/CeO2 of different shapes (nanocube and nanorod) are synthesized. The complete characterization of the support was performed. The effect of support shape, calcination temperature, and reduction temperature on SMR activity is found at different operating temperatures. For each condition conversion, CO, CO2 selectivity, and hydrogen yield are calculated. The results show the CeO2 morphology has a considerable effect on conversion, CO selectivity, and hydrogen yield. It is found that ceria nanocube calcined at 550°C provides better performance at high temperature. [ABSTRACT FROM AUTHOR]

Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same. [ABSTRACT FROM AUTHOR]